Morgan Stanley
DSGN icon

Morgan Stanley’s Design Therapeutics DSGN Stock Holding History

Morgan Stanley’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Buy
765,425
+108,860
+17% +$1.36M ﹤0.01% 3599
2026
Q1 		$6.99M Sell
656,565
-45,741
-7% -$463K ﹤0.01% 3871
2025
Q4 		$6.59M Buy
702,306
+526,315
+299% +$4.12M ﹤0.01% 3969
2025
Q3 		$1.33M Sell
175,991
-37,559
-18% -$188K ﹤0.01% 5021
2025
Q2 		$720K Sell
213,550
-34,328
-14% -$128K ﹤0.01% 5275
2025
Q1 		$957K Sell
247,878
-98,305
-28% -$469K ﹤0.01% 5020
2024
Q4 		$2.14M Sell
346,183
-82,615
-19% -$478K ﹤0.01% 4649
2024
Q3 		$2.31M Buy
428,798
+39,361
+10% +$185K ﹤0.01% 4546
2024
Q2 		$1.3M Sell
389,437
-88,655
-19% -$345K ﹤0.01% 4813
2024
Q1 		$1.93M Sell
478,092
-65,389
-12% -$175K ﹤0.01% 4611
2023
Q4 		$1.44M Buy
543,481
+183,223
+51% +$420K ﹤0.01% 4737
2023
Q3 		$850K Buy
360,258
+169,490
+89% +$791K ﹤0.01% 4893
2023
Q2 		$1.2M Buy
190,768
+121,391
+175% +$743K ﹤0.01% 4727
2023
Q1 		$400K Buy
69,377
+27,953
+67% +$209K ﹤0.01% 5379
2022
Q4 		$425K Sell
41,424
-17,511
-30% -$237K ﹤0.01% 5324
2022
Q3 		$985K Buy
58,935
+20,103
+52% +$400K ﹤0.01% 4892
2022
Q2 		$544K Buy
38,832
+26,016
+203% +$351K ﹤0.01% 5372
2022
Q1 		$207K Sell
12,816
-488
-4% -$7.47K ﹤0.01% 5906
2021
Q4 		$285K Buy
13,304
+5,900
+80% +$101K ﹤0.01% 5873
2021
Q3 		$108K Buy
7,404
+6,757
+1,044% +$112K ﹤0.01% 6320
2021
Q2 		$13K Buy
+647
New +$16.3K ﹤0.01% 7149

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley's DSGN Position: Q2 2026 in Review

Morgan Stanley increased its Design Therapeutics (DSGN) stake by 17% in Q2 2026, buying an estimated $1.36M and bringing the position to 765,425 shares worth $11.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3599.

Morgan Stanley first reported a position in DSGN in Q2 2021 and has held it in 21 quarters since. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Morgan Stanley held 765,425 shares of Design Therapeutics worth $11.1M as of Q2 2026.
  • Morgan Stanley bought 108,860 Design Therapeutics shares in Q2 2026, an estimated $1.36M.
  • Design Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3599 holding.
  • Morgan Stanley first reported a position in Design Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.